Screener
Gyre Therapeutics, Inc. GYRE Gyre Pharmaceuticals — Fair Value Adjustment Of Warrants
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:FairValueAdjustmentOfWarrants.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Other (loss) income, net: | ||
| Interest income | 941 | 1,797 |
| Other expense, net | (488)) | (301)) |
| Change in fair value of warrant liability | 212 | 2,467 |
| (Loss) Income before income taxes | (1,575)) | 4,265) |
| Benefit (provision) for income taxes | (662) | (1,563)) |
| Net (loss) income | (2,237)) | 2,702) |
| Accretion of Cullgen redeemable convertible preferred stock | (2,642)) | (5,220)) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s gyre pharmaceuticals — fair value adjustment of warrants?
- Gyre Therapeutics, Inc. (GYRE) reported gyre pharmaceuticals — fair value adjustment of warrants of -$0 in Q2 2026.
- What does gyre pharmaceuticals — fair value adjustment of warrants mean?
- This represents the non-cash gains or losses resulting from changes in the market value of outstanding warrants issued by the company. It reflects the impact of financial market volatility on the company's balance sheet and reported earnings.
Ask your AI about Gyre Therapeutics, Inc.'s gyre pharmaceuticals — fair value adjustment of warrants.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude